Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Appointments to SCRI's drug development programme

This article was originally published in Scrip

Executive Summary

Sarah Cannon Research Institute has promoted Dr Jeffrey Infante to director of drug development in Nashville, US, while Dr Howard Burris will assume the role of executive director for the overall drug development programme. Dr Burris, SCRI's CMO, will provide executive oversight of the drug development programmes in Nashville, Oklahoma, Florida and London. Dr Infante previously served as associate director of the Nashville based drug development programme.

Advertisement
Advertisement
UsernamePublicRestriction

Register

SC013202

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel